MERGE Selected as Agency of Record for Supernus Pharmaceuticals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: Newsfilter
- Expanded Partnership: MERGE has been selected as the Agency of Record for Supernus Pharmaceuticals, marking a significant deepening of their seven-year relationship aimed at enhancing brand communication through integrated digital marketing and technology platforms.
- Digital Ecosystem Leadership: Under the new agreement, MERGE will lead Supernus' entire digital ecosystem, including website development and CRM operations, which is expected to significantly enhance customer engagement and brand awareness.
- Product Portfolio Expansion: MERGE's role will extend beyond the Parkinson's portfolio to include marketing support for QELBREE, a non-stimulant treatment for ADHD, further strengthening Supernus' market position in the CNS disease sector.
- AI-Driven Innovation: MERGE will leverage AI technology to drive personalized marketing, enhancing customer experiences while ensuring compliance and targeting of brand messaging, thereby achieving greater success in the competitive biopharmaceutical market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SUPN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SUPN
Wall Street analysts forecast SUPN stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 43.580
Low
55.00
Averages
61.33
High
65.00
Current: 43.580
Low
55.00
Averages
61.33
High
65.00
About SUPN
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MERGE Selected as Agency of Record for Supernus Pharmaceuticals
- Expanded Partnership: MERGE has been selected as the Agency of Record for Supernus Pharmaceuticals, marking a significant deepening of their seven-year relationship aimed at enhancing brand communication through integrated digital marketing and technology platforms.
- Digital Ecosystem Leadership: Under the new agreement, MERGE will lead Supernus' entire digital ecosystem, including website development and CRM operations, which is expected to significantly enhance customer engagement and brand awareness.
- Product Portfolio Expansion: MERGE's role will extend beyond the Parkinson's portfolio to include marketing support for QELBREE, a non-stimulant treatment for ADHD, further strengthening Supernus' market position in the CNS disease sector.
- AI-Driven Innovation: MERGE will leverage AI technology to drive personalized marketing, enhancing customer experiences while ensuring compliance and targeting of brand messaging, thereby achieving greater success in the competitive biopharmaceutical market.
See More
Supernus Pharmaceuticals to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Supernus Pharmaceuticals will participate in the Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, showcasing its advancements in CNS disease treatments to attract investor interest.
- Live Webcast Availability: During the Jefferies conference, Supernus will provide a live audio webcast accessible through the Events & Presentations section of its website, enhancing transparency and convenience for potential investors, which is expected to improve the company's image among investors.
- Diverse Product Portfolio: Supernus focuses on developing products for various CNS disorders, including ADHD and Parkinson's disease-related dyskinesia, demonstrating its broad positioning in the biopharmaceutical sector, which may attract investors interested in novel drug development.
- Future Outlook and Risks: The company's press release includes forward-looking statements that highlight various risks, including the ability to maintain profitability and raise capital, which could impact its future financial performance and market competitiveness, necessitating investor vigilance.
See More
Quantedge Capital Fully Exits Supernus Pharmaceuticals Stake
- Complete Exit: Quantedge Capital sold all 89,600 shares of Supernus Pharmaceuticals in Q1 2026, with an estimated transaction value of $4.56 million, resulting in a net position value decrease of $4.45 million, indicating a cautious outlook on the company's future prospects.
- Significant Revenue Growth: Supernus Pharmaceuticals reported a 39% increase in Q1 revenue to $207.7 million, driven by rapid expansion of newer growth products, particularly with key products like Qelbree and GOCOVRI seeing a 56% revenue increase, showcasing the company's competitive position in the market.
- Enhanced Financial Flexibility: As of the end of Q1 2026, Supernus held approximately $384 million in cash and marketable securities, providing the company with the flexibility to continue investing in pipeline development and commercialization, reflecting a robust financial status in facing market challenges.
- Reduced Market Dependence: Supernus is decreasing its reliance on older epilepsy drugs, with Qelbree sales rising 20% to $77.9 million, while collaboration revenue from the Biogen-partnered ZURZUVAE contributed an additional $27.6 million, indicating a successful transition towards new product offerings.
See More
Supernus Pharmaceuticals CEO to Attend Healthcare Conference
- Conference Participation: Jack A. Khattar, CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Bank of America 2026 Healthcare Conference on May 12, 2026, at 3:40 p.m. PT in Las Vegas, showcasing the company's advancements in treating central nervous system diseases.
- Investor Engagement: Investors interested in meeting with company management during the conference can contact the Bank of America conference coordinator, enhancing communication and collaboration opportunities with stakeholders.
- Live Webcast: The presentation will be accessible via a live audio webcast on Supernus Pharmaceuticals' website, with an archived replay available for 60 days post-conference, ensuring that investors who cannot attend live can still access critical information.
- Product Portfolio: Supernus Pharmaceuticals focuses on treatments for CNS diseases, with a diverse portfolio including approved therapies for ADHD and Parkinson's disease-related dyskinesia, demonstrating the company's broad influence and market potential in the biopharmaceutical sector.
See More
Supernus Pharmaceuticals Q1 2026 Earnings Highlights
- Significant Revenue Growth: Supernus reported total revenues of $207.7 million for Q1 2026, reflecting a 39% year-over-year increase, with growth products seeing a remarkable 56% rise, indicating strong market performance and sustained product demand.
- ONAPGO Sales Outlook: ONAPGO generated net sales of $8.4 million in Q1, with regulatory submission to the FDA expected in Q3 2026, and potential market launch before mid-2027, which could provide a new revenue stream for the company.
- Strong ZURZUVAE Performance: ZURZUVAE contributed $27.6 million in collaboration revenues in Q1, with 85% of prescriptions coming from repeat prescribers, demonstrating high market acceptance and helping to solidify the company's market position.
- Enhanced Financial Flexibility: As of March 31, 2026, Supernus had approximately $384 million in cash and cash equivalents with no debt, providing significant financial flexibility for potential M&A and other growth opportunities in the future.
See More
Supernus Pharmaceuticals Q1 Earnings Beat Expectations
- Earnings Report: Supernus Pharmaceuticals reported a Q1 GAAP EPS of -$0.04, missing expectations by $0.03, indicating challenges in profitability despite revenue growth.
- Revenue Growth: The company achieved Q1 revenue of $207.7 million, a 38.6% year-over-year increase, exceeding market expectations by $14.78 million, reflecting strong product demand and market performance.
- 2026 Financial Guidance: Supernus projects GAAP operating earnings for 2026 to range from $0 to $30 million, with adjusted operating earnings expected between $140 million and $170 million, showcasing confidence in future growth.
- Asset Acquisition: Supernus finalized a $350 million acquisition of Navitor’s SPN-820 assets, which will enhance its product portfolio and drive long-term growth.
See More
MERGE Selected as Agency of Record for Supernus Pharmaceuticals
- Expanded Partnership: MERGE has been selected as the Agency of Record for Supernus Pharmaceuticals, marking a significant deepening of their seven-year relationship aimed at enhancing brand communication through integrated digital marketing and technology platforms.
- Digital Ecosystem Leadership: Under the new agreement, MERGE will lead Supernus' entire digital ecosystem, including website development and CRM operations, which is expected to significantly enhance customer engagement and brand awareness.
- Product Portfolio Expansion: MERGE's role will extend beyond the Parkinson's portfolio to include marketing support for QELBREE, a non-stimulant treatment for ADHD, further strengthening Supernus' market position in the CNS disease sector.
- AI-Driven Innovation: MERGE will leverage AI technology to drive personalized marketing, enhancing customer experiences while ensuring compliance and targeting of brand messaging, thereby achieving greater success in the competitive biopharmaceutical market.
See More
Supernus Pharmaceuticals to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Supernus Pharmaceuticals will participate in the Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, showcasing its advancements in CNS disease treatments to attract investor interest.
- Live Webcast Availability: During the Jefferies conference, Supernus will provide a live audio webcast accessible through the Events & Presentations section of its website, enhancing transparency and convenience for potential investors, which is expected to improve the company's image among investors.
- Diverse Product Portfolio: Supernus focuses on developing products for various CNS disorders, including ADHD and Parkinson's disease-related dyskinesia, demonstrating its broad positioning in the biopharmaceutical sector, which may attract investors interested in novel drug development.
- Future Outlook and Risks: The company's press release includes forward-looking statements that highlight various risks, including the ability to maintain profitability and raise capital, which could impact its future financial performance and market competitiveness, necessitating investor vigilance.
See More
Quantedge Capital Fully Exits Supernus Pharmaceuticals Stake
- Complete Exit: Quantedge Capital sold all 89,600 shares of Supernus Pharmaceuticals in Q1 2026, with an estimated transaction value of $4.56 million, resulting in a net position value decrease of $4.45 million, indicating a cautious outlook on the company's future prospects.
- Significant Revenue Growth: Supernus Pharmaceuticals reported a 39% increase in Q1 revenue to $207.7 million, driven by rapid expansion of newer growth products, particularly with key products like Qelbree and GOCOVRI seeing a 56% revenue increase, showcasing the company's competitive position in the market.
- Enhanced Financial Flexibility: As of the end of Q1 2026, Supernus held approximately $384 million in cash and marketable securities, providing the company with the flexibility to continue investing in pipeline development and commercialization, reflecting a robust financial status in facing market challenges.
- Reduced Market Dependence: Supernus is decreasing its reliance on older epilepsy drugs, with Qelbree sales rising 20% to $77.9 million, while collaboration revenue from the Biogen-partnered ZURZUVAE contributed an additional $27.6 million, indicating a successful transition towards new product offerings.
See More
Supernus Pharmaceuticals CEO to Attend Healthcare Conference
- Conference Participation: Jack A. Khattar, CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Bank of America 2026 Healthcare Conference on May 12, 2026, at 3:40 p.m. PT in Las Vegas, showcasing the company's advancements in treating central nervous system diseases.
- Investor Engagement: Investors interested in meeting with company management during the conference can contact the Bank of America conference coordinator, enhancing communication and collaboration opportunities with stakeholders.
- Live Webcast: The presentation will be accessible via a live audio webcast on Supernus Pharmaceuticals' website, with an archived replay available for 60 days post-conference, ensuring that investors who cannot attend live can still access critical information.
- Product Portfolio: Supernus Pharmaceuticals focuses on treatments for CNS diseases, with a diverse portfolio including approved therapies for ADHD and Parkinson's disease-related dyskinesia, demonstrating the company's broad influence and market potential in the biopharmaceutical sector.
See More
Supernus Pharmaceuticals Q1 2026 Earnings Highlights
- Significant Revenue Growth: Supernus reported total revenues of $207.7 million for Q1 2026, reflecting a 39% year-over-year increase, with growth products seeing a remarkable 56% rise, indicating strong market performance and sustained product demand.
- ONAPGO Sales Outlook: ONAPGO generated net sales of $8.4 million in Q1, with regulatory submission to the FDA expected in Q3 2026, and potential market launch before mid-2027, which could provide a new revenue stream for the company.
- Strong ZURZUVAE Performance: ZURZUVAE contributed $27.6 million in collaboration revenues in Q1, with 85% of prescriptions coming from repeat prescribers, demonstrating high market acceptance and helping to solidify the company's market position.
- Enhanced Financial Flexibility: As of March 31, 2026, Supernus had approximately $384 million in cash and cash equivalents with no debt, providing significant financial flexibility for potential M&A and other growth opportunities in the future.
See More
Supernus Pharmaceuticals Q1 Earnings Beat Expectations
- Earnings Report: Supernus Pharmaceuticals reported a Q1 GAAP EPS of -$0.04, missing expectations by $0.03, indicating challenges in profitability despite revenue growth.
- Revenue Growth: The company achieved Q1 revenue of $207.7 million, a 38.6% year-over-year increase, exceeding market expectations by $14.78 million, reflecting strong product demand and market performance.
- 2026 Financial Guidance: Supernus projects GAAP operating earnings for 2026 to range from $0 to $30 million, with adjusted operating earnings expected between $140 million and $170 million, showcasing confidence in future growth.
- Asset Acquisition: Supernus finalized a $350 million acquisition of Navitor’s SPN-820 assets, which will enhance its product portfolio and drive long-term growth.
See More
